论文部分内容阅读
目的 :探究米非司酮治疗子宫内膜异位症临床疗效。方法 :选取收治区间为2016年1月至2017年1月的84例子宫内膜异位症行保守手术治疗的患者作为本次临床研究资料,并将其随机平均分成两组,每小组有42例患者,对照组患者在手术后不用药物巩固治疗方法,观察组患者在术后使用米非司酮药物巩固治疗效果,判断两组患者在后期治疗过程中的体征改善情况,生殖激素变化情况以及不良反应等。结果 :观察组患者最终总有效率达到97.6%,而对照组患者最终治疗总有效率仅为85.7%,由此可见,观察组治疗效果明显优于对照组患者治疗效果,同时通过对两组患者LH、E2、P测定结果的数据分析,发现观察组数据指标优于对照组患者数据指标。结论 :米非司酮药物可以提高子宫内膜异位症的治疗效果,患者症状改善情况十分明显,在治疗过程中患者不良反应相对较少。
Objective: To investigate the clinical efficacy of mifepristone in the treatment of endometriosis. Methods: A total of 84 patients with endometriosis treated conservatively from January 2016 to January 2017 were enrolled as the data of this clinical study, and randomly divided into two groups with 42 Patients and control patients without drug consolidation after surgery, the observation group patients after treatment with mifepristone to consolidate the treatment effect, to determine the two groups of patients in the post-treatment process, signs of improvement, changes in reproductive hormones and Adverse reactions. Results: The final total effective rate of observation group reached 97.6%, while the control group patients the final total effective rate was only 85.7%, we can see that the treatment group was significantly better than the control group, the treatment effect, while the two groups of patients LH, E2, P measured results of the data analysis found that the observation group data indicators better than the control group patients data indicators. Conclusion: Mifepristone can improve the therapeutic effect of endometriosis. The improvement of symptoms in patients is obvious, and the adverse reactions in patients are relatively few.